- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02871518
Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
8 november 2016 bijgewerkt door: Hai-Qiang Mai,MD,PhD, Sun Yat-sen University
A Randomized Phase II Non-inferiority Study of Two Cycles Versus Three Cycles of Cisplatin Based Concurrent Chemoradiotherapy for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma Based on Pretreatment Plasma EBV DNA Level
This is a Phase II trial to study the effectiveness of two cycles versus three cycles of Concurrent Chemoradiotherapy in treating patients with Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma based on pretreatment plasma EBV DNA.
Studie Overzicht
Toestand
Onbekend
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia.
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced NPC.
Concurrently, although cisplatin-based concurrent chemoradiotherapy was considered as the standard regimen for locoregionally advanced nasopharyngeal carcinoma, several prospective randomized trials have demonstrated that only 52-63% patients can finished three cycles cisplatin-based concurrent chemoradiotherapy( DDP, 100mg/m2,D1,D22 and D43), due to chemoradiotherapy induced toxicity.
Combined analyses of NPC-9901 and NPC-9902 Trials indicated that the 5-year locoregional failure free survival was insignificant between the patients received between two and three cycles cisplatin-based concurrent chemoradiotherapy.
Our previous studies have also demonstrated that the five years overall survival, distant metastasis free survival and 5-year locoregional failure free survival was not observed significant difference between the patients received between two and three cycles cisplatin-based concurrent chemotherapy.
It indicated that one pressing questions remain to be resolved: can we define the optimal dose so that we can reduce toxicity by avoiding unnecessary overdose or an ineffective phase of treatment?
Recently, the quantification of pretreatment plasma Epstein-Barr virus (EBV) DNA, which was considered the most potential biomarker to compliment TNM stage, was demonstrated a useful biomarker for the risk stratification, monitoring and prediction of the prognosis of NPC.
The investigators previous study demonstrated that for local and regionally advanced NPC patients with EBV DNA <4,000copies/mL, the 3-year's PFS and DMFS was approximate to 90%.
Pretreatment plasma EBV DNA levels might be applied to guide concurrent chemotherapy regimen for local and regionally advanced NPC patients.
Therefore, the investigators make a hypothesis that the low risk locoregionally advanced NPC patients received two cycles of chemotherapy may gain similar long-term survival as those received three cycles of chemotherapy, leading to less chemotherapy induced toxicity.
Therefore, this phase II non-inferiority, randomised controlled clinical trial was designed to assess efficacy for low-risk patients, identified with pretreatment plasma EBV DNA <4,000 copies/mL, received two cycle cisplatin-based chemotherapy compared with three cycle cisplatin-based chemotherapy
Studietype
Ingrijpend
Inschrijving (Verwacht)
236
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Werving
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
-
Contact:
- Haiqiang Mai, MD,Ph.D
- Telefoonnummer: 86-20-8734-3643
- E-mail: maihq@mail.sysu.edu.cn
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 70 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III
- Original clinical staged as T3-4N0-3 M0 or any T、N2-3M0(according to the 7th AJCC edition)
- No evidence of distant metastasis (M0)
- Pretreatment Plasm EB Virus DNA<4000copies/ml
- Male and no pregnant female
- Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1
- WBC ≥ 4×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L
- With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 2.0×ULN)
- With normal renal function test (Creatinine ≤ 1.5×ULN)
Exclusion Criteria:
- Patients have evidence of relapse or distant metastasis
- Histologically confirmed keratinizing squamous cell carcinoma (WHO I)
- Receiving radiotherapy or chemotherapy previously
- The presence of uncontrolled life-threatening illness
- Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
- Receiving other ways of anti-cancer therapy.
- Suffered from other malignant tumors (except the cure of basal cell carcinoma or uterine cervical carcinoma in situ) previously.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Two cycle CCRT
Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
|
Concurrent cisplatin (100mg/m2,D1,D22) combine with IMRT
Andere namen:
Concurrent cisplatin (100mg/m2,D1,D22 and D43) combine with IMRT
Andere namen:
|
|
Actieve vergelijker: Three cycle CCRT
Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
|
Concurrent cisplatin (100mg/m2,D1,D22) combine with IMRT
Andere namen:
Concurrent cisplatin (100mg/m2,D1,D22 and D43) combine with IMRT
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progress-free survival
Tijdsspanne: 3 years
|
Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up
|
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The shor-term toxic effects
Tijdsspanne: 3 months
|
The shorterm toxic effects were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)
|
3 months
|
|
Complete Response (CR)
Tijdsspanne: after the completion of the chemoradiotherapy treatment (up to 9 weeks)
|
CR assessed by independent reviewers, according to the Modified Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI).
Disease response evaluated after the completion of the chemoradiotherapy treatment.
Complete response defined as the complete disappearance of the target and non-target lesion(s) identified at baseline after radiological evaluation by Magnetic Resonance Imaging (MRI) only
|
after the completion of the chemoradiotherapy treatment (up to 9 weeks)
|
|
Overall Survival(OS)
Tijdsspanne: 3 years
|
The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up
|
3 years
|
|
Locoregional Relapse-Free Survival(LRRFS)
Tijdsspanne: 3 years
|
The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit
|
3 years
|
|
Distant Metastasis-Free Survival (DMFS)
Tijdsspanne: 3 years
|
The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit
|
3 years
|
|
Cost-effectiveness analysis
Tijdsspanne: 3 years
|
The cost (including direct cost drug fees, inspection fees, expenses and nursing cost) and incremental cost-effectiveness ratio was calculated between two arms
|
3 years
|
|
The monitoring of plasma EBV DNA
Tijdsspanne: 3 years
|
The plasma EBV DNA will be detected before treatment ,during treatment (weekly) and during follow up( every 3-6 months)
|
3 years
|
|
Long-term toxicities
Tijdsspanne: 3 years
|
Patients will be monitored for long-term toxicity by standard NIH criteria.
QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30) and EORTC QLQ Head and Neck
|
3 years
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 augustus 2016
Primaire voltooiing (Verwacht)
1 juli 2018
Studie voltooiing (Verwacht)
1 juli 2021
Studieregistratiedata
Eerst ingediend
17 juli 2016
Eerst ingediend dat voldeed aan de QC-criteria
17 augustus 2016
Eerst geplaatst (Schatting)
18 augustus 2016
Updates van studierecords
Laatste update geplaatst (Schatting)
10 november 2016
Laatste update ingediend die voldeed aan QC-criteria
8 november 2016
Laatst geverifieerd
1 november 2016
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata per site
- Neoplasmata, glandulair en epitheel
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Hoofd- en nekneoplasmata
- Nasofaryngeale ziekten
- Faryngeale ziekten
- Stomatognatische ziekten
- KNO-ziekten
- Nasofaryngeale neoplasmata
- Carcinoom
- Nasofarynxcarcinoom
- Antineoplastische middelen
- Cisplatine
Andere studie-ID-nummers
- cycle of CCRT and NPC
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
ONBESLIST
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .